Skeletal accumulation of bisphosphonates: Implications for osteoporosis treatment

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 11, 2008, Pages 1371-1378

  Allen, Matthew R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti remodeling agents; Bisphosphonates; Osteonecrosis of the jaw; Osteoporosis treatment; Remodeling suppression

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

BINDING AFFINITY; BONE MATRIX; BONE NECROSIS; BONE REMODELING; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG STRUCTURE; DRUG WITHDRAWAL; FOLLOW UP; FRACTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAW DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SKELETON;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CYTOSKELETON; DIPHOSPHONATES; HUMANS; JAW; OSTEONECROSIS; OSTEOPOROSIS;

EID: 56749118082     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.11.1371     Document Type: Review

References (61)

1. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19(6):733-59
2. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007;86(11):1022-33
3. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97(12):2692-6
4. Fleisch H, Felix R. Diphosphonates. Calcif Tissue Int 1979;27(2):91-4
5. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006;38(5):617-27
6. Leu CT, Luegmayr E, Freedman LP, et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006;38(5):628-36
7. Lin JH, Chen IW, Deluna FA. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake. Drug Metab Dispos 1994;22(3):400-5
8. Lin JH, Chen IW, Deluna FA, Hichens M. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther 1993;267(2):670-5
9. Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991;19(5):926-32
10. Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992;20(4):473-8
11. Peter CP, Guy J, Shea M, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone. J Pharmacol Exp Ther 1996;276(1):271-6
12. Bauss F, Lalla S, Endele R, Hothorn LA. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 2002;29(10):2200-8
13. Endele R, Loew H, Bauss F. Analytical methods for the quantification of ibandronate in body fluids and bone. J Pharm Biomed Anal 2005;39(1-2):246-5
14. King LE, Grynpas MD, Tomlinson G, Vieth R. Pamidronate content and turnover in sternum, vertebral body, and iliac bones of dogs. Bone 1997;20(5):405-11
15. Komatsubara S, Mori S, Mashiba T, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003;18(3):512-20
16. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004;19(6):999-1005
17. Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient. 4th edition. New York: Academic Press; 1990
18. Lin JH, Chen IW, Deluna FA. On the absorption of alendronate in rats. J Pharm Sci 1994;83(12):1741-6
19. Usui T, Watanabe T, Higuchi S. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metab Dispos 1995;23(11):1214-9
20. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88(6):2095-105
21. Bauss F, Pfister T, Papapoulos S. Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 2008;26(4):406-8
22. Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992;7(5):513-22
23. Black DM, Schwartz AV, Ensrud KE, et al. Effecus of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38
24. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41
25. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280(24):2077-82
26. Colon-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA 2006;296(24):2968-9
27. Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008 May 16. [Epub ahead of print]
28. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19(3):365-72
29. Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-7
30. Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11(6 Pt 1):622-30
31. Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000;85(4):1492-7
32. Ravn P, Christensen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 1998;22(5):559-64
33. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137(11):875-83
34. Wronski TJ, Dann LM, Qi H, Yen CF. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calcif Tissue Int 1993;53(3):210-216
35. Tamura Y, Miyakoshi N, Itoi E, et al. Long-term effeccs of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. J Bone Miner Res 2001; 16(3):541-9
36. Fuchs RK, Phipps RJ, Burr DB. Recovery of trabecular and cortical bone turnover following discontinuation of Risedronate and Alendronate therapy in ovariectomized rats. J Bone Miner Res 2008;23(10):1689-97
37. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349(13):1207-15
38. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349(13):1216-26
39. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19(5):745-51
40. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to Teriparatide following therapy with Alendronate or Risedronate. J Clin Enclocrinol Metab 2008 Aug 5 [Epub ahead of print]
41. Gasser JA, Kneissel M, Thomsen JS, Mosekilde L. PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 2000;1(1):53-6
42. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91
43. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007;86(11):1013-21
44. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35(3):155-60
45. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66(5):987-94
46. Allen MR. Bisphosphonates and Osteonecrosis of the Jaw: Moving From the 'Bedside to the Bench'. Cells, Tissues, Organs 2008; In Press
47. Huja SS, Fernandez SA, Hill KJ, Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 2006;288(12):1243-9
48. Garetto LP, Tricker ND. Remodeling of bone surrounding the implant interface. In: Garetto LP, Turner CH, Duncan RL, Burr DB, editors, Bridging the Gap Between Dental & Orthopaedic Implants, 3rd Annual Indiana Conference; Indianapolis, IN 1998
49. Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2008 Jul 23 [Epub ahead of print]
50. Plotkin LI, Aguirre JI, Kousteni S, et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005;280(8):7317-25
51. Idris AI, Rojas J, Greig IR, et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro Calcif Tissue Int 2008;82(3):191-201
52. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19(3):281-90
53. Roelofs AJ, Coxon FP, Ebetino FH, et al. Use of a fluorescent analogue of risedronate to study localization and cellular uptake of bisphosphonates in vivo Bone 2008;42:S85
54. Kline WF, Matuszewski BK. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 1992;583(2):183-93
55. King LE, Vieth R. Extraction and measurement of pamidronate from bone samples using automated pre-column derivatization, high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Appl 1996;678(2):325-30
56. Pan H, Sima M, Kopeckova P, et al. Biodistribution and Pharmacokinetic Studies of Bone-Targeting N-(2-Hydroxypropyl) methacrylamide Copolymer-Alendronate Conjugates. Mol Pharm 2008;5(4):548-58
57. Wang D, Sima M, Mosley RL, et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl) methacrylamide copolymers. Mol Pharm 2006;3(6):717-25
58. Wang D, Miller SC, Shlyakhtenko LS, et al. Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug Chem 2007;18(5):1375-8
59. Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008;42(5):848-60
60. Wang D, Miller S, Sima M, et al. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 2003;14(5):853-9
61. Kozloff KM, Weissleder R, Mahmood U. Noninvasive optical detection of bone mineral. J Bone Miner Res 2007;22(8):1208-16